CTI BIOPHARMA CORP (CTIC)

US12648L6011 - Common Stock

9.09  0 (0%)

After market: 9.09 0 (0%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
53.948M127.1M
135.60%
EBITDA
YoY % growth
-43.04M
-9.32%
-94.806M
-120.27%
-77.846M
17.89%
N/AN/AN/AN/AN/AN/AN/AN/A
EBIT
YoY % growth
-43.57M
-9.14%
-95.332M
-118.80%
-79.797M
16.30%
-23.106M
71.04%
Operating Margin
N/AN/A-147.91%-18.18%
EPS
YoY % growth
-0.69-1.08
-56.52%
-0.85
21.30%
-0.28
66.63%
N/AN/AN/A

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q2 / 23 Q3 / 23 Q4 / 23 Q1 / 24 Q2 / 24 Q3 / 24 Q4 / 24
EPS
Q2Q % growth
-0.08
61.35%
Revenue
Q2Q % growth
28.221M
128.90%
EBITDA
Q2Q % growth
N/AN/AN/AN/AN/AN/AN/A
EBIT
Q2Q % growth
-7.18M
61.97%

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q1 2023
Q2Q % growth
-0.10
72.97%
-0.120.0215.56%
Q4 2022
Q2Q % growth
-0.14
63.16%
-0.10-0.04-41.98%
Q3 2022
Q2Q % growth
-0.13
50.00%
-0.160.0318.65%
Q2 2022
Q2Q % growth
-0.21 -0.210.00-2.21%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q1 2023
Q2Q % growth
24.116M
950.81%
23.407M709K3.03%
Q4 2022
Q2Q % growth
21.083M
∞%
23.969M-2.886M-12.04%
Q3 2022
Q2Q % growth
18.241M
∞%
17.511M730K4.17%
Q2 2022
Q2Q % growth
12.329M
∞%
9.279M3.05M32.87%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS0% -6.62% 0% -3674.68%
Revenue0% -11.03% 0% -20.6%